Navigation Links
Oncothyreon reports second quarter 2010 financial results
Date:8/5/2010

KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., resumed the worldwide clinical development program for Stimuvax(R) in non-small cell lung cancer (NSCLC), including the Phase 3 START and INSPIRE trials, following a decision by the U.S. Food and Drug Administration (FDA) to partially lift the clinical hold it placed on the Investigational New Drug (IND) application for Stimuvax in March 2010. Treatment of existing patients and enrollment of new patients in START is again underway at most centers. The clinical hold for the Phase 3 STRIDE trial in advanced breast cancer was not lifted by the FDA, and in July Merck Serono decided to close this trial.

PX-866 - Phase 1 clinical trial data for PX-866, an irreversible inhibitor of PI-3 kinase, were presented at the American Society of Clinical Oncology meeting in June. The trial was an open-label, dose escalation study in patients with advanced metastatic cancer of both an intermittent and a continuous dosing schedule, including an expansion cohort at the maximum tolerated dose for each schedule.

PX-866 was well-tolerated in both arms of this trial. The most common adverse events were mild to moderate in severity, and included diarrhea, nausea, vomiting, fatigue and reversible elevation of liver enzymes. There was no significant increase in adverse events noted in patients receiving more than two cycles of treatment in either arm of the trial.

In the continuous dosing arm, 6 of 8 patients evaluable at the time of the presentation (or 75 percent) had stable disease as the best response. In the intermittent dosing arm, 7 out of 45 evaluable patients (or 16 percent) experienced stable disease. Enrollment of additional patients in the continuous dosing arm has now been completed; additional data will be presented at the 22nd EORTC-NCI-AACR sym
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces second quarter 2010 financial results conference call
2. Oncothyreon announces presentations at upcoming investor conferences in June
3. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
4. Oncothyreon reports full year and fourth quarter 2009 financial results
5. Oncothyreon reports first quarter 2010 financial results
6. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
7. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
8. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
9. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
10. Oncothyreon announces webcast of third quarter 2009 financial results conference call
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/7264hm/biomarkers ) has announced ... "Biomarkers - Technologies, Markets and Companies" to ... broad definition of a biomarker as a characteristic ... an indicator of normal biological or pathogenic processes ... intervention. Tests based on biomarkers have been around ...
(Date:6/2/2015)... --  Hospira, Inc. (NYSE: HSP ), a ... – a global biopharmaceutical company – has received approval ... Brazil – for Remsima (infliximab), ... Brazil . The medication will be ... infliximab in 26 European countries and in ...
(Date:6/2/2015)... Md. , June 2, 2015   ... leader in synthetic biology, announced today the appointment ... Senior Vice President, Consumer Sector.  Mr. Jarry will ... solutions in products and applications for consumer markets.  ... over 30 years of experience in leading global ...
(Date:6/2/2015)... June 2, 2015  Alere Inc. (NYSE: ... joined the White House Antibiotic Stewardship Forum today ... support and advance the President,s National Action Plan ... a number of measurable goals and objectives over ... help healthcare providers protect their patients through antibiotic ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2
... Syngenta and DuPont today announced that Syngenta has ... 8, 2010. The transaction dissolves a joint venture between ... enables Syngenta and Pioneer to pursue independent licensing strategies ... biotechnology traits. Davor Pisk, Chief Operating ...
... 9, 2010 Reportlinker.com announces that a new market ... Biomarkers - technologies,markets and companies ... This report follows the broad definition ... objectively measured and evaluated as an indicator of normal ...
... 2010 Cardium Therapeutics (NYSE Amex: CXM ... third quarter ended September 30, 2010.  Highlights of the ... market launch of Cardium,s MedPodium product line, a portfolio ... nutraceuticals and aesthetics designed to promote and manage personal ...
Cached Biology Technology:Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 2Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 3Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 2Reportlinker Adds Biomarkers - Technologies, Markets And Companies 3Reportlinker Adds Biomarkers - Technologies, Markets And Companies 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 5Reportlinker Adds Biomarkers - Technologies, Markets And Companies 6Reportlinker Adds Biomarkers - Technologies, Markets And Companies 7Reportlinker Adds Biomarkers - Technologies, Markets And Companies 8Reportlinker Adds Biomarkers - Technologies, Markets And Companies 9Reportlinker Adds Biomarkers - Technologies, Markets And Companies 10Reportlinker Adds Biomarkers - Technologies, Markets And Companies 11Reportlinker Adds Biomarkers - Technologies, Markets And Companies 12Reportlinker Adds Biomarkers - Technologies, Markets And Companies 13Reportlinker Adds Biomarkers - Technologies, Markets And Companies 14Reportlinker Adds Biomarkers - Technologies, Markets And Companies 15Reportlinker Adds Biomarkers - Technologies, Markets And Companies 16Reportlinker Adds Biomarkers - Technologies, Markets And Companies 17Reportlinker Adds Biomarkers - Technologies, Markets And Companies 18Reportlinker Adds Biomarkers - Technologies, Markets And Companies 19Reportlinker Adds Biomarkers - Technologies, Markets And Companies 20Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 2Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 3Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 4Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 5Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 6Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 7Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 8Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments 9
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... Scientists have found that a large proportion of infants ... disease. The disease is the most prevalent acute wheezing ... admission to hospital in the first year of life in ... admitted to hospital for bronchiolitis - needing oxygen and help ...
... from small rings of naturally occurring plant DNA can ... embryonic plants where they are expressed, duplicated as plant ... -- a long-term goal for those interested in improving ... issue of PLoS-Genetics, a team of academic and commercial ...
... Research Hospital have identified the cell that gives rise to ... growth and development. The finding suggests for the first time ... induce fully developed neurons to multiply and coax the injured ... work appears in the Oct. 19 issue of the journal ...
Cached Biology News:Scientists find predisposition to bronchiolitis in some babies 2Transgenics transformed 2Transgenics transformed 3St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 2St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 3
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (C6921) ... assistance. Mfr Desig: Corning ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... culture scale-up, these culture chambers produce cell ... 9 range and are useful alternatives ... • High mechanical • strength and structural ... shipping • Certified nonpyrogenic and sterilized by ...
Biology Products: